The American Society for Clinical Investigation (ASCI) honors Frederick Kofi Korley, MD, PhD, with the 2026 ASCI/Louis W. Sullivan, MD, Award. Dr. Korley is recognized for his pioneering research in acute care diagnostics and therapeutics, and his impactful commitment to training physician-scientists. He is Professor and Associate Chair for Research in Emergency Medicine at the University of Michigan as well as Scientific Director of the Massey TBI [traumatic brain injury] Grand Challenge, sponsored by the University of Michigan Weil Institute. Dr. Korley chairs the American College of Emergency Physicians TBI expert panel and was the 2021 recipient of the Society of Academic Emergency Medicine Mid-Career Investigator Award. He was elected to the ASCI in 2024. ASCI President-Elect Dr. Stephen Y. Chan, Vitalant Chair in Vascular Medicine and Professor of Medicine and Director of the Vascular Medicine Institute at the University of Pittsburgh School of Medicine and UPMC, interviewed Dr. Korley at the AAP/ASCI/APSA Joint Meeting in Chicago in April 2026.
In this episode, James Crowe describes how these studies support the development of CCHFV countermeasures to induce protection against GP38 in vivo.
In this episode, Fumihiko Urano describes how the manuscript reports 24- and 48-week results from the ongoing HELIOS trial (ClinicalTrials.gov NCT05676034), a single-center, single-arm, open-label, phase II trial of PB&TURSO. Collectively, these results support continued development of PB&TURSO.
In this episode, Guido Beldi and Lilian Salm explain how their findings suggest that large peritoneal macrophages (LPMs), strategically positioned in the peritoneal cavity, serve as a source of circulating fibronectin, promoting matrix formation and accelerating wound healing at distant sites.
In this episode, Xiang-Yu Liu explains that the manuscript's findings revise the conventional view of GSH in protein redox and demonstrate that targeted redox manipulation through GSH depletion protects against MASLD.